2.810USD-1.40%Mkt Cap: 566.28M $P/E: —2d ago
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The company offers INTERCEPT Blood System, a propriet…
Industry Peers
Medical Devices$203.17BUSDP/E 37.7
$126.37BUSDP/E 34.2
$119.49BUSDP/E 25.0
$73.00BUSDP/E 20.4
$48.43BUSDP/E 19.9
$51.70BUSDP/E 53.4
$34.85BUSDP/E 36.5
$34.04BUSDP/E 17.2
$25.08BUSDP/E 20.7
$26.80BUSDP/E 20.8
$23.20BUSDP/E 29.1
$19.26BUSDP/E 24.5
$12.81BUSDP/E 79.7
$12.25BUSDP/E 19.9
$11.48BUSDP/E 19.8
$11.67BUSDP/E 22.2
$10.91BUSD
$10.01BUSDP/E 17.1
$10.28BUSDP/E 27.5
$10.17BUSDP/E 46.3
| Headline | Source | Time |
|---|---|---|
Older | ||
 Cerus Q2 Earnings Call Highlights Cerus (NASDAQ:CERS) reported second-quarter product revenue growth of 10% year over year and raised the low end of its 2026 product revenue outlook, citing demand for its INTERCEPT blood-safety products in North America and overseas. Product revenue totaled $57.4 million for the quarter ended June | ||
IInsider Monkey | ||